Nano-X Imaging Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNOX research report →
Range $3 – $3
Price Chart
About the company
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging.
- CEO
- Erez I. Meltzer
- IPO
- 2020
- Employees
- 197
- HQ
- Petah Tikva, IL
Get TickerSpark's AI analysis on NNOX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.73M
- P/E
- -0.14
- PEG
- 0.00
- P/S
- 1.16
- P/B
- 0.22
- EV/EBITDA
- 0.06
- Div Yield
- 0.00%
- Gross Margin
- -338.20%
- Op Margin
- -654.94%
- Net Margin
- -747.20%
- ROE
- -94.35%
- ROIC
- -123.96%
Latest fiscal year · YoY change
- Revenue
- $13.02M+15.4%
- Gross Profit
- $-12,788,000-20.5%
- Op Income
- $-60,699,000
- Net Income
- $-75,018,000-40.2%
- EPS
- $-1.16-27.5%
- OCF Growth
- -11.5%
- FCF Growth
- -14.3%
- 52W High
- $4.71
- 52W Low
- $0.21
- 50D MA
- $0.47
- 200D MA
- $1.40
- Beta
- 1.36
- RSI (14)
- 30
- Avg Volume
- 2.67M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nanox posted higher Q2 revenue but a much larger GAAP loss due to a $40.7 million impairment, while management emphasized commercialization progress, cost cuts, and new reimbursement pathways.· September 9, 2026
- Q2 revenue rose 37% year over year to $4.2 million, helped by Nanox Health IT consolidation and growth in teleradiology and AI/software.
- GAAP net loss widened to $55.5 million, mainly because of a $40.7 million impairment charge tied to AI assets.
- Non-GAAP gross margin improved to -13% from -21%, but adjusted EBITDA loss increased to $11.3 million from $10.4 million.
- Management said commercialization is progressing but slower than expected, with more impact expected in the next few months.
- The company is cutting costs, including a 15% reduction in Israeli headcount and about 67% of Korea headcount, with about $2 million of annualized savings expected starting in 2027.
- Nanox highlighted new U.S. distribution partnerships, RadNet activity, first patients scanned in Philadelphia, and a CMS reimbursement code for Nanox.AI cardiac analysis.
Q2 2026 revenue was $4.2 million versus $3.0 million in Q2 2025, up 37% year over year. Revenue included $3.0 million from teleradiology services, $1.0 million from AI and software solutions, and $0.2 million from imaging systems and OEM services. Adjusted EBITDA loss was $11.3 million versus $10.4 million a year ago. GAAP gross loss margin was -1,051% versus -107%, while non-GAAP gross loss margin was -13% versus -21%. GAAP net loss was $55.5 million versus $14.7 million, and non-GAAP net loss was $11.6 million versus $10.9 million. The quarter included a $40.7 million impairment charge to cost of revenue, reducing the fair value of certain AI intangible assets to $1.9 million. Cash and cash equivalents plus restricted deposits were $31.4 million at June 30, 2026, down from $60 million at December 31, 2025. After quarter-end, Nanox raised $8.5 million of gross proceeds through an ATM program and a registered direct offering. Management did not provide formal next-quarter or full-year revenue guidance, but said the impact of commercialization progress should start to show in the next few months. It also said annualized cost savings of about $2 million from workforce and Korea restructuring are expected to begin in 2027.
Erez Meltzer framed the quarter as one of operational progress rather than clean financial improvement, saying the company has completed a business review and is implementing lessons learned across commercial, operational, and strategic priorities. He stressed that commercialization has taken longer than expected, mainly because deployments require permitting, shielding, construction, and integration work at imaging centers. His tone was constructive but cautious: he emphasized new partnerships, the first Nanox Imaging Network site scanning patients, RadNet workflow integration, and broader clinical use cases, while also saying the company is still in the early stages of proving the model.
Guy Nathanzon focused on liquidity, burn reduction, and restructuring. He said the company reduced Israeli headcount by 15% and Korean headcount by about 67%, expects about $2 million of annualized savings beginning in 2027, and will rely on OEM partners for chip supply. He also said Nanox raised $8.5 million of gross proceeds after quarter-end to improve the cash balance. On the quarter, he cited $4.2 million of revenue, $11.3 million of adjusted EBITDA loss, $31.4 million of cash and restricted deposits, and the $40.7 million impairment charge, which did not affect cash but drove the GAAP loss.
Analysts focused on the timing of revenue traction, the size and placement pipeline, the impairment, and how much more cost reduction could come out of the business. Management said placements were made in Greece, Romania, and the Czech Republic, with systems for Peru and Argentina awaiting import licenses, plus U.S. activity including a conversion from MSaaS to CapEx, an IDN installation, an urgent care installation, and three Nanox Imaging Network systems, one already scanning. On timing, Erez said the company expects to see the impact of current commercialization efforts in the next few months. On reimbursement, he said the CMS code for Nanox.AI is already in place and that the imaging network already has reimbursed revenue, though he declined to quantify additional OpEx cuts beyond the Korea actions.
The call showed multiple commercial signs of life: new U.S. distribution agreements, RadNet integration, first patients scanned in Philadelphia, and sites reportedly doing hundreds of scans per month. Management also pointed to a new CMS reimbursement code for Nanox.AI cardiac analysis and said the imaging network has already seen paid claims, which could support broader adoption. The company is also cutting fixed costs and trying to extend runway while building a more scalable channel model.
The biggest concern remains that commercialization is moving slower than expected and is still not translating into strong revenue growth. The quarter included a large $40.7 million impairment and a much wider GAAP loss, while cash fell to $31.4 million before the post-quarter capital raise. Management also declined to give precise targets for future revenue or additional expense reductions, and several deployments are still waiting on import licenses or broader execution steps.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 71.3%
- Shares Outstanding
- 78.75M
- Float Shares
- 56.13M
of shares held by institutions
109 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Marshall Wace, Llp | 1.09M | ▲ 309.73K |
| Ark Investment Management LLC | 806.61K | ▲ 73.32K |
| Aqr Capital Management LLC | 560.60K | ▲ 65.90K |
| Blackrock, Inc. | 472.44K | ▼ 123.60K |
| Bank Of America Corp | 456.78K | ▼ 27.55K |
| Vanguard Group Inc | 400.45K | ▲ 10.12K |
| Morgan Stanley | 356.75K | ▼ 298.05K |
| Goldman Sachs Group Inc | 348.57K | ▼ 30.37K |
| Susquehanna International Group, Llp | 325.31K | ▲ 226.15K |
| Renaissance Technologies LLC | 316.21K | ▲ 316.21K |
| Jain Global LLC | 304.20K | ▲ 304.20K |
| Royal Bank Of Canada | 246.23K | ▲ 52.06K |
Held by 10 ETFs
Biggest fund positions in NNOX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 19, 26 | Meltzer Erez | buy | 25,000 |
| Oct 14, 26 | Yahav Attias Gali | other | 28,283 |
| Oct 14, 26 | saban sharon | other | 28,283 |
| Oct 14, 26 | Nathansohn Guy | other | 50,000 |
| Oct 13, 26 | Gofman Feler Marina | other | 28,283 |
| Oct 11, 26 | Dara James | other | 28,283 |
| Oct 10, 26 | Koren Ofir | other | 28,283 |
| Oct 11, 26 | Aharon Cohen Tamar | other | 28,283 |
| Sep 15, 26 | Meltzer Erez | buy | 10,000 |
| Sep 14, 26 | Suesskind Dan S | buy | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NNOX coverage
Recent articles, reports, and earnings notes.
No research on NNOX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNOX report →Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026
globenewswire.com · Nov 18
Nanox to Report Third Quarter 2026 Financial Results on November 25, 2026
globenewswire.com · Nov 16
Nanox Announces Distribution Agreement with Medworks for Nanox.AI in Greece
globenewswire.com · Nov 13
Nanox.AI Advances Commercial Collaboration with Dosy Health to Bring AI Cardiac Solution to Thailand
globenewswire.com · Nov 10
Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures
globenewswire.com · Nov 9
USARAD, a Nanox Company, Expands Collaboration with AZmed to Integrate FDA-Cleared X-ray AI into Its Teleradiology Workflows
globenewswire.com · Nov 9
TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI's AVC Solution
globenewswire.com · Nov 2
Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026
globenewswire.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.